Faeth Therapeutics (FTH) Retained Earnings (2020 - 2026)

Faeth Therapeutics (FTH) has reported Retained Earnings for 7 consecutive years, with -$469.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Retained Earnings fell 71.38% year-over-year to -$469.4 million; the trailing twelve-month figure through Jun 2026 stood at -$469.4 million (down 71.38% YoY), and the FY2025 full-year result was -$283.1 million, down 8.05% from the prior year.
• Retained Earnings slipped to -$469.4 million in Q2 2026 per FTH's latest filing, from -$453.4 million in the prior quarter.
• Across five years, Retained Earnings topped out at -$161.6 million in Q1 2022 and bottomed at -$469.4 million in Q2 2026.
• Historically, Retained Earnings has averaged -$257.2 million across 5 years, with a median of -$243.5 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Retained Earnings dropped 8.05% in 2025, then slumped 71.38% in 2026.
• Over 5 years, Retained Earnings stood at -$197.8 million in 2022, then fell by 17.24% to -$231.9 million in 2023, then dropped by 13.0% to -$262.1 million in 2024, then dropped by 8.05% to -$283.1 million in 2025, then plunged by 65.79% to -$469.4 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered -$469.4 million, -$453.4 million, and -$283.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.